$295.99 USD
Ver más detalles
Descripcion
Indice
Autores
Muestra
Ficha Técnica
Descripción

Covering all aspects of molecular pathology as it relates to the transformation and pathogenesis of cancer, this award-winning volume in the Diagnostic Pathology series is an expert resource for pathologists at all levels of experience and training, both as a quick reference and as an efficient review to improve knowledge and skills. This easily accessible, point-of-care reference features templated, bulleted content that is generously illustrated with charts, graphs, tables, and color photomicrographs of histology with special stains. It offers a practical, clinical approach to examining how molecular mutations affect common medical diseases and identifies the relevant and appropriate molecular tests to perform for a complete work-up in the era of molecular-targeted therapies.

  • Provides updated information on molecular mutations in different tumors, including solid tumors and hematopoietic neoplasms, and new targeted therapies geared toward these molecular alterations
  • Discusses now widely used immunotherapy treatments, including how immunotherapy has revolutionized the treatment of many neoplasms such as breast and lung carcinomas and lymphoma
  • Features more than 2,000 annotated images throughout, including H&E stains, immunostains, and FISH images
  • Covers timely topics such as:
    • Recent advances in cancer immunotherapy, specifically in the molecular basis of immunotherapy
    • Newly discovered targeted therapies, including multiple lung carcinoma therapies now considered for patients based on existing mutations to specific genes (KRAS, ALK, BRAF, and ROS)
    • The need for integration of myeloid and lymphoid gene panels due to increased knowledge from next generation sequencing studies of new mutations and the resulting newly developed molecular targets
    • Increased usage of next generation sequencing techniques
    • Changes to hematopoietic tumor details based on revised WHO guidelines
  • Recipient of a 2016 BMA Award: Highly Commended, Pathology (previous edition)

1. SECTION 1: INTRODUCTION - p. xiii 2. List of Tables - p. xiii 3. Chapter 1: Structure of Chromosomes and Nucleic Acids - p. xiii 4. Chapter 2: DNA Replication, Transcription, and Translation - p. 7 5. Chapter 3: Gene Mutations - p. 11 6. SECTION 2: COMMON TECHNIQUES FOR ANALYSIS OF ALTERATIONS IN CHROMOSOMES AND DNA - p. 15 7. Chapter 4: Cytogenetics and FISH - p. 15 8. Chapter 5: Chromosomal Microarray - p. 21 9. Chapter 6: Amplification Methods - p. 25 10. Chapter 7: DNA High-Resolution Melting Curve Analysis - p. 29 11. Chapter 8: Sequencing Technologies - p. 31 12. Chapter 9: High-Throughput Methods in Molecular Pathology - p. 33 13. Chapter 10: DNA Methylation Analysis - p. 35 14. SECTION 3: MOLECULAR GENETIC TESTS IN HEMATOPOIETIC TUMORS - p. 37 15. Chapter 11: BCR-ABL1 Fusion Gene - p. 37 16. Chapter 12: PML-RARA Fusion Gene - p. 43 17. Chapter 13: Reverse Transcription PCR for Other Myeloid Leukemia Transcripts - p. 45 18. Chapter 14: FLT3, NPM1, and CEBPA Mutations - p. 47 19. Chapter 15: JAK2 Mutations and Rearrangements - p. 51 20. Chapter 16: MPL Mutations - p. 53 21. Chapter 17: Calreticulin (CALR) Mutations - p. 55 22. Chapter 18: CSF3R Mutations - p. 57 23. Chapter 19: SETBP1 Mutations - p. 59 24. Chapter 20: KIT Mutations - p. 61 25. Chapter 21: IDH1 and IDH2 Mutations - p. 65 26. Chapter 22: Other Mutations and Gene Panel Testing in Myeloid Neoplasms - p. 67 27. Chapter 23: Immunoglobulin Heavy (IGH) Chain Gene Rearrangements - p. 69 28. Chapter 24: T-Cell Receptor Gamma (TRG) and Delta (TRD) Chain Rearrangements - p. 73 29. Chapter 25: T-Cell Receptor Beta (TRB) Chain Gene Rearrangements - p. 77 30. Chapter 26: Southern Blot Analysis of Antigen Receptor Genes - p. 81 31. Chapter 27: EBV-Associated Human Neoplasms - p. 83 32. Chapter 28: MYD88 Mutation - p. 91 33. Chapter 29: NOTCH1 Mutation - p. 93 34. Chapter 30: EZH2 Mutation - p. 95 35. SECTION 4: MOLECULAR GENETIC TESTS IN SOLID TUMORS, BONE AND SOFT TISSUE TUMORS, AND CNS TUMORS - p. 99 36. Chapter 31: ALK Gene Rearrangements and Mutations - p. 99 37. Chapter 32: ROS1 Rearrangements - p. 103 38. Chapter 33: RET Rearrangements - p. 105 39. Chapter 34: FISH for MET Amplifications - p. 107 40. Chapter 35: FISH for ERBB2 (HER2) Gene Amplifications - p. 111 41. Chapter 36: KRAS Mutations - p. 113 42. Chapter 37: BRAF Mutations - p. 115 43. Chapter 38: EGFR Mutations - p. 117 44. Chapter 39: Targeted Hotspot Gene Panel Using Massively Parallel Sequencing (Next-Generation Sequencing) - p. 119 45. Chapter 40: Targeted Hotspot Gene Panel Table - p. 121 46. Chapter 41: MGMT Promoter Gene Methylation Assay - p. 127 47. SECTION 5: MOLECULAR PATHOLOGY OF MYELOID NEOPLASMS - p. 129 48. Chapter 42: Molecular Work-Up of Myeloid Neoplasms - p. 129 49. MYELOPROLIFERATIVE NEOPLASMS - p. 133 50. Chapter 43: Chronic Myeloid Leukemia, BCR-ABL1 Positive - p. 133 51. Chapter 44: Chronic Neutrophilic Leukemia - p. 141 52. Chapter 45: Polycythemia Vera - p. 145 53. Chapter 46: Primary Myelofibrosis - p. 149 54. Chapter 47: Essential Thrombocythemia - p. 153 55. Chapter 48: Chronic Eosinophilic Leukemia, NOS - p. 157 56. Chapter 49: Myeloproliferative Neoplasms, Unclassifiable - p. 159 57. MASTOCYTOSIS - p. 163 58. Chapter 50: Mastocytosis - p. 163 59. MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND GENE REARRANGEMENT - p. 171 60. Chapter 51: Myeloid/Lymphoid Neoplasms With Eosinophilia and Gene Rearrangement - p. 171 61. MYELODYSPLASTIC SYNDROME (MDS) - p. 175 62. Chapter 52: Overview and Classification of Myelodysplastic Syndrome - p. 175 63. Chapter 53: Myelodysplastic Syndromes With Single-Lineage Dysplasia - p. 179 64. Chapter 54: Myelodysplastic Syndrome With Ring Sideroblasts - p. 183 65. Chapter 55: Myelodysplastic Syndrome With Multilineage Dysplasia - p. 187 66. Chapter 56: Myelodysplastic Syndrome With Isolated del(5q) - p. 191 67. Chapter 57: Myelodysplastic Syndrome, Unclassifiable - p. 195 68. Chapter 58: Childhood Myelodysplastic Syndrome and Refractory Cytopenia of Childhood - p. 199 69. MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS - p. 205 70. Chapter 59: Overview of Myelodysplastic/Myeloproliferative Neoplasms - p. 205 71. Chapter 60: Chronic Myelomonocytic Leukemia - p. 207 72. Chapter 61: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative - p. 211 73. Chapter 62: Juvenile Myelomonocytic Leukemia - p. 215 74. Chapter 63: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable - p. 217 75. ACUTE MYELOID LEUKEMIA - p. 221 76. Chapter 64: Overview of Acute Myeloid Leukemia - p. 221 77. Chapter 65: Acute Myeloid Leukemia With t(8;21); RUNX1-RUNX1T1 - p. 229 78. Chapter 66: Acute Myeloid Leukemia With inv(16) or t(16;16); CBFB-MYH11 - p. 233 79. Chapter 67: Acute Promyelocytic Leukemia With t(15;17); PML-RARA - p. 237 80. Chapter 68: Acute Myeloid Leukemia With t(9;11); MLLT3-KMT2A - p. 243 81. Chapter 69: Acute Myeloid Leukemia With t(6:9); DEK-NUP214 - p. 247 82. Chapter 70: Acute Myeloid Leukemia With inv(3) or t(3;3); GATA2, MECOM - p. 249 83. Chapter 71: Acute Myeloid Leukemia (Megakaryoblastic) With t(1;22); RBM15-MRTFA - p. 251 84. Chapter 72: Acute Myeloid Leukemia With Myelodysplasia-Related Changes - p. 253 85. Chapter 73: Acute Myeloid Leukemia, NOS - p. 255 86. Chapter 74: Therapy-Related Myeloid Neoplasms - p. 261 87. Chapter 75: Myeloid Sarcoma - p. 267 88. Chapter 76: Myeloid Proliferations Associated With Down Syndrome - p. 271 89. BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM - p. 275 90. Chapter 77: Blastic Plasmacytoid Dendritic Cell Neoplasm - p. 275 91. SECTION 6: MOLECULAR PATHOLOGY OF LYMPHOID NEOPLASMS - p. 281 92. Chapter 78: Overview of Lymphoid Neoplasms - p. 281 93. Chapter 79: Molecular Work-Up of Lymphoid Neoplasms - p. 287 94. DETERMINATION OF CLONALITY IN B-, T-, AND NK-CELL NEOPLASMS - p. 289 95. Chapter 80: Lymphoma-Associated Chromosomal Translocations - p. 289 96. PRECURSOR LYMPHOID NEOPLASMS - p. 293 97. Chapter 81: B-Lymphoblastic Leukemia/Lymphoma With Recurrent Genetic Abnormalities - p. 293 98. Chapter 82: B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like (Ph-Like ALL) - p. 297 99. Chapter 83: T-Lymphoblastic Leukemia/Lymphoma - p. 301 100. MATURE B-CELL NEOPLASMS - p. 307 101. Chapter 84: Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia - p. 307 102. Chapter 85: B-Cell Prolymphocytic Leukemia - p. 313 103. Chapter 86: Splenic Marginal Zone Lymphoma - p. 317 104. Chapter 87: Hairy Cell Leukemia - p. 323 105. Chapter 88: Splenic B-Cell Lymphoma/Leukemia, Unclassifiable - p. 327 106. Chapter 89: Lymphoplasmacytic Lymphoma - p. 333 107. Chapter 90: Monoclonal Gammopathy of Undetermined Significance - p. 339 108. Chapter 91: Plasma Cell Myeloma - p. 343 109. Chapter 92: Follicular Lymphoma - p. 351 110. Chapter 93: Mantle Cell Lymphoma - p. 357 111. Chapter 94: Diffuse Large B-Cell Lymphoma - p. 363 112. Chapter 95: Burkitt Lymphoma - p. 373 113. MATURE T- AND NK-CELL NEOPLASMS - p. 381 114. Chapter 96: T-Cell Prolymphocytic Leukemia - p. 381 115. Chapter 97: Chronic Lymphoproliferative Disorder of NK Cells - p. 385 116. Chapter 98: Aggressive NK-Cell Leukemia - p. 389 117. Chapter 99: Extranodal NK-/T-Cell Lymphoma, Nasal Type - p. 393 118. Chapter 100: Adult T-Cell Leukemia/Lymphoma - p. 397 119. Chapter 101: Intestinal T-Cell Lymphoma - p. 403 120. Chapter 102: Hepatosplenic T-Cell Lymphoma - p. 409 121. Chapter 103: Subcutaneous Panniculitis-Like T-Cell Lymphoma - p. 413 122. Chapter 104: Mycosis Fungoides/Sézary Syndrome - p. 417 123. Chapter 105: Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders - p. 421 124. Chapter 106: Peripheral T-Cell Lymphoma, NOS - p. 425 125. Chapter 107: Angioimmunoblastic T-Cell Lymphoma - p. 431 126. Chapter 108: Anaplastic Large Cell Lymphoma, ALK Negative - p. 437 127. Chapter 109: Anaplastic Large Cell Lymphoma, ALK Positive - p. 443 128. SECTION 7: MOLECULAR PATHOLOGY OF DENDRITIC CELL AND HISTIOCYTIC NEOPLASMS - p. 449 129. Chapter 110: Histiocytic Sarcoma - p. 449 130. Chapter 111: Tumors Derived From Langerhans Cells - p. 459 131. Chapter 112: Interdigitating Dendritic Cell Tumor - p. 465 132. Chapter 113: Follicular Dendritic Cell Neoplasm - p. 469 133. SECTION 8: MOLECULAR PATHOLOGY OF SOLID TUMORS - p. 473 134. HEAD AND NECK, INCLUDING SINONASAL TUMORS AND SALIVARY GLANDS - p. 473 135. Chapter 114: HPV-Associated Head and Neck Carcinomas - p. 473 136. Chapter 115: Head and Neck Mucosal Squamous Cell Carcinoma, Non-HPV Related - p. 481 137. Chapter 116: Important Alterations in Non-HPV-Related Head and Neck Squamous Cell Carcinoma - p. 487 138. Chapter 117: Translocation-Specific Salivary Gland Tumors 1 - p. 489 139. Chapter 118: Translocation-Specific Salivary Gland Tumors 2 - p. 497 140. Chapter 119: Nasopharyngeal EBV-Related Squamous Cell Carcinoma - p. 505 141. Chapter 120: Other Head and Neck Tumors - p. 509 142. THYROID - p. 517 143. Chapter 121: Papillary Thyroid Carcinoma - p. 517 144. Chapter 122: Follicular Thyroid Carcinoma - p. 521 145. Chapter 123: Poorly Differentiated Thyroid Carcinoma - p. 525 146. Chapter 124: Undifferentiated Thyroid Carcinoma - p. 529 147. Chapter 125: Medullary Thyroid Carcinoma - p. 533 148. LUNG - p. 539 149. Chapter 126: Adenocarcinoma, Lung - p. 539 150. Chapter 127: Squamous Cell Carcinoma, Lung - p. 547 151. Chapter 128: Small Cell Neuroendocrine Carcinoma - p. 551 152. Chapter 129: Mesothelioma - p. 555 153. LUMINAL GASTROINTESTINAL TRACT - p. 557 154. Chapter 130: Gastric Adenocarcinoma - p. 557 155. Chapter 131: Colorectal Adenocarcinoma and Precancerous Lesions - p. 561 156. Chapter 132: Gastrointestinal Stromal Tumor - p. 567 157. LIVER - p. 575 158. Chapter 133: HNF1α-Inactivated Hepatocellular Adenoma - p. 575 159. Chapter 134: β-Catenin-Activated Hepatocellular Adenoma - p. 579 160. Chapter 135: Inflammatory Hepatocellular Adenoma - p. 583 161. Chapter 136: Hepatocellular Carcinoma - p. 587 162. PANCREATICOBILIARY - p. 591 163. Chapter 137: Pancreatic Ductal Adenocarcinoma - p. 591 164. Chapter 138: Pancreatic Mucinous Cystic Neoplasm - p. 595 165. Chapter 139: Pancreatic Intraductal Papillary Mucinous Neoplasm - p. 597 166. Chapter 140: Cholangiocarcinoma - p. 599 167. TESTIS - p. 601 168. Chapter 141: Testicular Germ Cell Tumors - p. 601 169. KIDNEY - p. 607 170. Chapter 142: Clear Cell Renal Cell Carcinoma - p. 607 171. Chapter 143: Chromophobe Renal Cell Carcinoma - p. 611 172. Chapter 144: Papillary Renal Cell Carcinoma - p. 613 173. Chapter 145: MiT Family Translocation Renal Cell Carcinomas - p. 615 174. Chapter 146: Wilms Tumor - p. 619 175. Chapter 147: Clear Cell Sarcoma of Kidney - p. 625 176. Chapter 148: Oncocytoma - p. 627 177. Chapter 149: Rhabdoid Tumor of Kidney - p. 629 178. BLADDER - p. 631 179. Chapter 150: Urothelial Carcinoma - p. 631 180. ADRENAL - p. 637 181. Chapter 151: Pheochromocytoma/Paraganglioma - p. 637 182. Chapter 152: Adrenal Cortical Carcinoma - p. 643 183. Chapter 153: Neuroblastoma - p. 649 184. Chapter 154: Adrenal Cortical Adenoma - p. 657 185. PROSTATE - p. 661 186. Chapter 155: Prostatic Adenocarcinoma, Acinar Type and High-Grade Prostatic Intraepithelial Neoplasia - p. 661 187. BREAST - p. 665 188. Chapter 156: ADH and DCIS (Dysplastic, Premalignant) - p. 665 189. Chapter 157: Ductal Carcinomas - p. 669 190. Chapter 158: Lobular Carcinoma - p. 675 191. Chapter 159: Carcinoma With Medullary Features, Breast - p. 681 192. Chapter 160: Metaplastic Breast Carcinoma - p. 687 193. Chapter 161: Phyllodes Tumors - p. 693 194. Chapter 162: Basal-Like and Triple-Negative Carcinomas - p. 699 195. CERVIX/VULVA/VAGINA - p. 709 196. Chapter 163: Preneoplastic Conditions, Cervix/Vulva/Vagina - p. 709 197. Chapter 164: Squamous Cell Carcinoma, Cervix/Vulva/Vagina - p. 713 198. Chapter 165: Adenocarcinoma, Cervix/Vulva/Vagina - p. 717 199. UTERUS - p. 721 200. Chapter 166: Endometrial Intraepithelial Neoplasia - p. 721 201. Chapter 167: Uterine Endometrioid Carcinoma - p. 723 202. Chapter 168: Uterine Serous Carcinoma - p. 727 203. Chapter 169: Clear Cell Carcinoma, Uterus - p. 729 204. Chapter 170: Uterine Sarcomas - p. 733 205. OVARIES/FALLOPIAN TUBE - p. 741 206. Chapter 171: Serous Tumors of Ovary and Fallopian Tube - p. 741 207. Chapter 172: Other Surface Epithelial Tumors of Ovary - p. 747 208. Chapter 173: Sex Cord-Stromal Tumors of Ovary - p. 753 209. Chapter 174: Germ Cell Tumor, Ovary - p. 759 210. SKIN - p. 763 211. Chapter 175: Preneoplastic Conditions, Skin - p. 763 212. Chapter 176: Melanoma - p. 767 213. Chapter 177: Squamous Cell Carcinoma, Skin - p. 771 214. Chapter 178: Basal Cell Carcinoma, Skin - p. 775 215. Chapter 179: Other Skin Conditions - p. 779 216. BONE - p. 783 217. Chapter 180: Overview of Molecular Pathology of Bone and Soft Tissue Tumors - p. 783 218. Chapter 181: Osteosarcomas - p. 789 219. Chapter 182: Ewing Sarcoma - p. 797 220. Chapter 183: Other Small Round Blue Cell Sarcomas - p. 803 221. Chapter 184: Giant Cell Tumor of Bone - p. 809 222. Chapter 185: Intermediate and Malignant Cartilaginous Tumors of Bone - p. 815 223. SOFT TISSUE - p. 825 224. Chapter 186: Intermediate and Malignant Myofibroblastic/Fibroblastic Tumors - p. 825 225. Chapter 187: Liposarcomas - p. 835 226. Chapter 188: Muscle Sarcomas - p. 845 227. Chapter 189: Intermediate and Malignant Vascular Tumors - p. 855 228. Chapter 190: Malignant Peripheral Nerve Sheath Tumor - p. 863 229. Chapter 191: Representative Genetic Findings in Bone and Soft Tissue Tumors - p. 869 230. SARCOMAS OF UNCERTAIN DIFFERENTIATION - p. 875 231. Chapter 192: Rare Sarcomas of Uncertain Differentiation With Specific Molecular Alterations - p. 875 232. CNS - p. 885 233. Chapter 193: High-Grade Astrocytoma - p. 885 234. Chapter 194: Low-Grade Astrocytoma - p. 889 235. Chapter 195: Pilocytic Astrocytoma - p. 893 236. Chapter 196: Oligodendroglioma - p. 897 237. Chapter 197: Ependymoma - p. 901 238. Chapter 198: Medulloblastoma - p. 907 239. Chapter 199: Choroid Plexus Tumors - p. 913 240. Chapter 200: Meningioma - p. 917 241. Chapter 201: Retinoblastoma - p. 921 242. SECTION 9: QUALITY ASSURANCE AND REGULATORY ISSUES - p. 925 243. Chapter 202: Federal Agencies and Regulation of Laboratories - p. 925 244. Chapter 203: FDA Regulations - p. 929 245. Chapter 204: Proficiency Testing and Accreditation - p. 935 246. INDEX - p. 939

No hay muestra disponible

No hay ficha técnica disponible

Descripcion
Descripción

Covering all aspects of molecular pathology as it relates to the transformation and pathogenesis of cancer, this award-winning volume in the Diagnostic Pathology series is an expert resource for pathologists at all levels of experience and training, both as a quick reference and as an efficient review to improve knowledge and skills. This easily accessible, point-of-care reference features templated, bulleted content that is generously illustrated with charts, graphs, tables, and color photomicrographs of histology with special stains. It offers a practical, clinical approach to examining how molecular mutations affect common medical diseases and identifies the relevant and appropriate molecular tests to perform for a complete work-up in the era of molecular-targeted therapies.

  • Provides updated information on molecular mutations in different tumors, including solid tumors and hematopoietic neoplasms, and new targeted therapies geared toward these molecular alterations
  • Discusses now widely used immunotherapy treatments, including how immunotherapy has revolutionized the treatment of many neoplasms such as breast and lung carcinomas and lymphoma
  • Features more than 2,000 annotated images throughout, including H&E stains, immunostains, and FISH images
  • Covers timely topics such as:
    • Recent advances in cancer immunotherapy, specifically in the molecular basis of immunotherapy
    • Newly discovered targeted therapies, including multiple lung carcinoma therapies now considered for patients based on existing mutations to specific genes (KRAS, ALK, BRAF, and ROS)
    • The need for integration of myeloid and lymphoid gene panels due to increased knowledge from next generation sequencing studies of new mutations and the resulting newly developed molecular targets
    • Increased usage of next generation sequencing techniques
    • Changes to hematopoietic tumor details based on revised WHO guidelines
  • Recipient of a 2016 BMA Award: Highly Commended, Pathology (previous edition)

1. SECTION 1: INTRODUCTION - p. xiii 2. List of Tables - p. xiii 3. Chapter 1: Structure of Chromosomes and Nucleic Acids - p. xiii 4. Chapter 2: DNA Replication, Transcription, and Translation - p. 7 5. Chapter 3: Gene Mutations - p. 11 6. SECTION 2: COMMON TECHNIQUES FOR ANALYSIS OF ALTERATIONS IN CHROMOSOMES AND DNA - p. 15 7. Chapter 4: Cytogenetics and FISH - p. 15 8. Chapter 5: Chromosomal Microarray - p. 21 9. Chapter 6: Amplification Methods - p. 25 10. Chapter 7: DNA High-Resolution Melting Curve Analysis - p. 29 11. Chapter 8: Sequencing Technologies - p. 31 12. Chapter 9: High-Throughput Methods in Molecular Pathology - p. 33 13. Chapter 10: DNA Methylation Analysis - p. 35 14. SECTION 3: MOLECULAR GENETIC TESTS IN HEMATOPOIETIC TUMORS - p. 37 15. Chapter 11: BCR-ABL1 Fusion Gene - p. 37 16. Chapter 12: PML-RARA Fusion Gene - p. 43 17. Chapter 13: Reverse Transcription PCR for Other Myeloid Leukemia Transcripts - p. 45 18. Chapter 14: FLT3, NPM1, and CEBPA Mutations - p. 47 19. Chapter 15: JAK2 Mutations and Rearrangements - p. 51 20. Chapter 16: MPL Mutations - p. 53 21. Chapter 17: Calreticulin (CALR) Mutations - p. 55 22. Chapter 18: CSF3R Mutations - p. 57 23. Chapter 19: SETBP1 Mutations - p. 59 24. Chapter 20: KIT Mutations - p. 61 25. Chapter 21: IDH1 and IDH2 Mutations - p. 65 26. Chapter 22: Other Mutations and Gene Panel Testing in Myeloid Neoplasms - p. 67 27. Chapter 23: Immunoglobulin Heavy (IGH) Chain Gene Rearrangements - p. 69 28. Chapter 24: T-Cell Receptor Gamma (TRG) and Delta (TRD) Chain Rearrangements - p. 73 29. Chapter 25: T-Cell Receptor Beta (TRB) Chain Gene Rearrangements - p. 77 30. Chapter 26: Southern Blot Analysis of Antigen Receptor Genes - p. 81 31. Chapter 27: EBV-Associated Human Neoplasms - p. 83 32. Chapter 28: MYD88 Mutation - p. 91 33. Chapter 29: NOTCH1 Mutation - p. 93 34. Chapter 30: EZH2 Mutation - p. 95 35. SECTION 4: MOLECULAR GENETIC TESTS IN SOLID TUMORS, BONE AND SOFT TISSUE TUMORS, AND CNS TUMORS - p. 99 36. Chapter 31: ALK Gene Rearrangements and Mutations - p. 99 37. Chapter 32: ROS1 Rearrangements - p. 103 38. Chapter 33: RET Rearrangements - p. 105 39. Chapter 34: FISH for MET Amplifications - p. 107 40. Chapter 35: FISH for ERBB2 (HER2) Gene Amplifications - p. 111 41. Chapter 36: KRAS Mutations - p. 113 42. Chapter 37: BRAF Mutations - p. 115 43. Chapter 38: EGFR Mutations - p. 117 44. Chapter 39: Targeted Hotspot Gene Panel Using Massively Parallel Sequencing (Next-Generation Sequencing) - p. 119 45. Chapter 40: Targeted Hotspot Gene Panel Table - p. 121 46. Chapter 41: MGMT Promoter Gene Methylation Assay - p. 127 47. SECTION 5: MOLECULAR PATHOLOGY OF MYELOID NEOPLASMS - p. 129 48. Chapter 42: Molecular Work-Up of Myeloid Neoplasms - p. 129 49. MYELOPROLIFERATIVE NEOPLASMS - p. 133 50. Chapter 43: Chronic Myeloid Leukemia, BCR-ABL1 Positive - p. 133 51. Chapter 44: Chronic Neutrophilic Leukemia - p. 141 52. Chapter 45: Polycythemia Vera - p. 145 53. Chapter 46: Primary Myelofibrosis - p. 149 54. Chapter 47: Essential Thrombocythemia - p. 153 55. Chapter 48: Chronic Eosinophilic Leukemia, NOS - p. 157 56. Chapter 49: Myeloproliferative Neoplasms, Unclassifiable - p. 159 57. MASTOCYTOSIS - p. 163 58. Chapter 50: Mastocytosis - p. 163 59. MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND GENE REARRANGEMENT - p. 171 60. Chapter 51: Myeloid/Lymphoid Neoplasms With Eosinophilia and Gene Rearrangement - p. 171 61. MYELODYSPLASTIC SYNDROME (MDS) - p. 175 62. Chapter 52: Overview and Classification of Myelodysplastic Syndrome - p. 175 63. Chapter 53: Myelodysplastic Syndromes With Single-Lineage Dysplasia - p. 179 64. Chapter 54: Myelodysplastic Syndrome With Ring Sideroblasts - p. 183 65. Chapter 55: Myelodysplastic Syndrome With Multilineage Dysplasia - p. 187 66. Chapter 56: Myelodysplastic Syndrome With Isolated del(5q) - p. 191 67. Chapter 57: Myelodysplastic Syndrome, Unclassifiable - p. 195 68. Chapter 58: Childhood Myelodysplastic Syndrome and Refractory Cytopenia of Childhood - p. 199 69. MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS - p. 205 70. Chapter 59: Overview of Myelodysplastic/Myeloproliferative Neoplasms - p. 205 71. Chapter 60: Chronic Myelomonocytic Leukemia - p. 207 72. Chapter 61: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative - p. 211 73. Chapter 62: Juvenile Myelomonocytic Leukemia - p. 215 74. Chapter 63: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable - p. 217 75. ACUTE MYELOID LEUKEMIA - p. 221 76. Chapter 64: Overview of Acute Myeloid Leukemia - p. 221 77. Chapter 65: Acute Myeloid Leukemia With t(8;21); RUNX1-RUNX1T1 - p. 229 78. Chapter 66: Acute Myeloid Leukemia With inv(16) or t(16;16); CBFB-MYH11 - p. 233 79. Chapter 67: Acute Promyelocytic Leukemia With t(15;17); PML-RARA - p. 237 80. Chapter 68: Acute Myeloid Leukemia With t(9;11); MLLT3-KMT2A - p. 243 81. Chapter 69: Acute Myeloid Leukemia With t(6:9); DEK-NUP214 - p. 247 82. Chapter 70: Acute Myeloid Leukemia With inv(3) or t(3;3); GATA2, MECOM - p. 249 83. Chapter 71: Acute Myeloid Leukemia (Megakaryoblastic) With t(1;22); RBM15-MRTFA - p. 251 84. Chapter 72: Acute Myeloid Leukemia With Myelodysplasia-Related Changes - p. 253 85. Chapter 73: Acute Myeloid Leukemia, NOS - p. 255 86. Chapter 74: Therapy-Related Myeloid Neoplasms - p. 261 87. Chapter 75: Myeloid Sarcoma - p. 267 88. Chapter 76: Myeloid Proliferations Associated With Down Syndrome - p. 271 89. BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM - p. 275 90. Chapter 77: Blastic Plasmacytoid Dendritic Cell Neoplasm - p. 275 91. SECTION 6: MOLECULAR PATHOLOGY OF LYMPHOID NEOPLASMS - p. 281 92. Chapter 78: Overview of Lymphoid Neoplasms - p. 281 93. Chapter 79: Molecular Work-Up of Lymphoid Neoplasms - p. 287 94. DETERMINATION OF CLONALITY IN B-, T-, AND NK-CELL NEOPLASMS - p. 289 95. Chapter 80: Lymphoma-Associated Chromosomal Translocations - p. 289 96. PRECURSOR LYMPHOID NEOPLASMS - p. 293 97. Chapter 81: B-Lymphoblastic Leukemia/Lymphoma With Recurrent Genetic Abnormalities - p. 293 98. Chapter 82: B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like (Ph-Like ALL) - p. 297 99. Chapter 83: T-Lymphoblastic Leukemia/Lymphoma - p. 301 100. MATURE B-CELL NEOPLASMS - p. 307 101. Chapter 84: Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia - p. 307 102. Chapter 85: B-Cell Prolymphocytic Leukemia - p. 313 103. Chapter 86: Splenic Marginal Zone Lymphoma - p. 317 104. Chapter 87: Hairy Cell Leukemia - p. 323 105. Chapter 88: Splenic B-Cell Lymphoma/Leukemia, Unclassifiable - p. 327 106. Chapter 89: Lymphoplasmacytic Lymphoma - p. 333 107. Chapter 90: Monoclonal Gammopathy of Undetermined Significance - p. 339 108. Chapter 91: Plasma Cell Myeloma - p. 343 109. Chapter 92: Follicular Lymphoma - p. 351 110. Chapter 93: Mantle Cell Lymphoma - p. 357 111. Chapter 94: Diffuse Large B-Cell Lymphoma - p. 363 112. Chapter 95: Burkitt Lymphoma - p. 373 113. MATURE T- AND NK-CELL NEOPLASMS - p. 381 114. Chapter 96: T-Cell Prolymphocytic Leukemia - p. 381 115. Chapter 97: Chronic Lymphoproliferative Disorder of NK Cells - p. 385 116. Chapter 98: Aggressive NK-Cell Leukemia - p. 389 117. Chapter 99: Extranodal NK-/T-Cell Lymphoma, Nasal Type - p. 393 118. Chapter 100: Adult T-Cell Leukemia/Lymphoma - p. 397 119. Chapter 101: Intestinal T-Cell Lymphoma - p. 403 120. Chapter 102: Hepatosplenic T-Cell Lymphoma - p. 409 121. Chapter 103: Subcutaneous Panniculitis-Like T-Cell Lymphoma - p. 413 122. Chapter 104: Mycosis Fungoides/Sézary Syndrome - p. 417 123. Chapter 105: Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders - p. 421 124. Chapter 106: Peripheral T-Cell Lymphoma, NOS - p. 425 125. Chapter 107: Angioimmunoblastic T-Cell Lymphoma - p. 431 126. Chapter 108: Anaplastic Large Cell Lymphoma, ALK Negative - p. 437 127. Chapter 109: Anaplastic Large Cell Lymphoma, ALK Positive - p. 443 128. SECTION 7: MOLECULAR PATHOLOGY OF DENDRITIC CELL AND HISTIOCYTIC NEOPLASMS - p. 449 129. Chapter 110: Histiocytic Sarcoma - p. 449 130. Chapter 111: Tumors Derived From Langerhans Cells - p. 459 131. Chapter 112: Interdigitating Dendritic Cell Tumor - p. 465 132. Chapter 113: Follicular Dendritic Cell Neoplasm - p. 469 133. SECTION 8: MOLECULAR PATHOLOGY OF SOLID TUMORS - p. 473 134. HEAD AND NECK, INCLUDING SINONASAL TUMORS AND SALIVARY GLANDS - p. 473 135. Chapter 114: HPV-Associated Head and Neck Carcinomas - p. 473 136. Chapter 115: Head and Neck Mucosal Squamous Cell Carcinoma, Non-HPV Related - p. 481 137. Chapter 116: Important Alterations in Non-HPV-Related Head and Neck Squamous Cell Carcinoma - p. 487 138. Chapter 117: Translocation-Specific Salivary Gland Tumors 1 - p. 489 139. Chapter 118: Translocation-Specific Salivary Gland Tumors 2 - p. 497 140. Chapter 119: Nasopharyngeal EBV-Related Squamous Cell Carcinoma - p. 505 141. Chapter 120: Other Head and Neck Tumors - p. 509 142. THYROID - p. 517 143. Chapter 121: Papillary Thyroid Carcinoma - p. 517 144. Chapter 122: Follicular Thyroid Carcinoma - p. 521 145. Chapter 123: Poorly Differentiated Thyroid Carcinoma - p. 525 146. Chapter 124: Undifferentiated Thyroid Carcinoma - p. 529 147. Chapter 125: Medullary Thyroid Carcinoma - p. 533 148. LUNG - p. 539 149. Chapter 126: Adenocarcinoma, Lung - p. 539 150. Chapter 127: Squamous Cell Carcinoma, Lung - p. 547 151. Chapter 128: Small Cell Neuroendocrine Carcinoma - p. 551 152. Chapter 129: Mesothelioma - p. 555 153. LUMINAL GASTROINTESTINAL TRACT - p. 557 154. Chapter 130: Gastric Adenocarcinoma - p. 557 155. Chapter 131: Colorectal Adenocarcinoma and Precancerous Lesions - p. 561 156. Chapter 132: Gastrointestinal Stromal Tumor - p. 567 157. LIVER - p. 575 158. Chapter 133: HNF1α-Inactivated Hepatocellular Adenoma - p. 575 159. Chapter 134: β-Catenin-Activated Hepatocellular Adenoma - p. 579 160. Chapter 135: Inflammatory Hepatocellular Adenoma - p. 583 161. Chapter 136: Hepatocellular Carcinoma - p. 587 162. PANCREATICOBILIARY - p. 591 163. Chapter 137: Pancreatic Ductal Adenocarcinoma - p. 591 164. Chapter 138: Pancreatic Mucinous Cystic Neoplasm - p. 595 165. Chapter 139: Pancreatic Intraductal Papillary Mucinous Neoplasm - p. 597 166. Chapter 140: Cholangiocarcinoma - p. 599 167. TESTIS - p. 601 168. Chapter 141: Testicular Germ Cell Tumors - p. 601 169. KIDNEY - p. 607 170. Chapter 142: Clear Cell Renal Cell Carcinoma - p. 607 171. Chapter 143: Chromophobe Renal Cell Carcinoma - p. 611 172. Chapter 144: Papillary Renal Cell Carcinoma - p. 613 173. Chapter 145: MiT Family Translocation Renal Cell Carcinomas - p. 615 174. Chapter 146: Wilms Tumor - p. 619 175. Chapter 147: Clear Cell Sarcoma of Kidney - p. 625 176. Chapter 148: Oncocytoma - p. 627 177. Chapter 149: Rhabdoid Tumor of Kidney - p. 629 178. BLADDER - p. 631 179. Chapter 150: Urothelial Carcinoma - p. 631 180. ADRENAL - p. 637 181. Chapter 151: Pheochromocytoma/Paraganglioma - p. 637 182. Chapter 152: Adrenal Cortical Carcinoma - p. 643 183. Chapter 153: Neuroblastoma - p. 649 184. Chapter 154: Adrenal Cortical Adenoma - p. 657 185. PROSTATE - p. 661 186. Chapter 155: Prostatic Adenocarcinoma, Acinar Type and High-Grade Prostatic Intraepithelial Neoplasia - p. 661 187. BREAST - p. 665 188. Chapter 156: ADH and DCIS (Dysplastic, Premalignant) - p. 665 189. Chapter 157: Ductal Carcinomas - p. 669 190. Chapter 158: Lobular Carcinoma - p. 675 191. Chapter 159: Carcinoma With Medullary Features, Breast - p. 681 192. Chapter 160: Metaplastic Breast Carcinoma - p. 687 193. Chapter 161: Phyllodes Tumors - p. 693 194. Chapter 162: Basal-Like and Triple-Negative Carcinomas - p. 699 195. CERVIX/VULVA/VAGINA - p. 709 196. Chapter 163: Preneoplastic Conditions, Cervix/Vulva/Vagina - p. 709 197. Chapter 164: Squamous Cell Carcinoma, Cervix/Vulva/Vagina - p. 713 198. Chapter 165: Adenocarcinoma, Cervix/Vulva/Vagina - p. 717 199. UTERUS - p. 721 200. Chapter 166: Endometrial Intraepithelial Neoplasia - p. 721 201. Chapter 167: Uterine Endometrioid Carcinoma - p. 723 202. Chapter 168: Uterine Serous Carcinoma - p. 727 203. Chapter 169: Clear Cell Carcinoma, Uterus - p. 729 204. Chapter 170: Uterine Sarcomas - p. 733 205. OVARIES/FALLOPIAN TUBE - p. 741 206. Chapter 171: Serous Tumors of Ovary and Fallopian Tube - p. 741 207. Chapter 172: Other Surface Epithelial Tumors of Ovary - p. 747 208. Chapter 173: Sex Cord-Stromal Tumors of Ovary - p. 753 209. Chapter 174: Germ Cell Tumor, Ovary - p. 759 210. SKIN - p. 763 211. Chapter 175: Preneoplastic Conditions, Skin - p. 763 212. Chapter 176: Melanoma - p. 767 213. Chapter 177: Squamous Cell Carcinoma, Skin - p. 771 214. Chapter 178: Basal Cell Carcinoma, Skin - p. 775 215. Chapter 179: Other Skin Conditions - p. 779 216. BONE - p. 783 217. Chapter 180: Overview of Molecular Pathology of Bone and Soft Tissue Tumors - p. 783 218. Chapter 181: Osteosarcomas - p. 789 219. Chapter 182: Ewing Sarcoma - p. 797 220. Chapter 183: Other Small Round Blue Cell Sarcomas - p. 803 221. Chapter 184: Giant Cell Tumor of Bone - p. 809 222. Chapter 185: Intermediate and Malignant Cartilaginous Tumors of Bone - p. 815 223. SOFT TISSUE - p. 825 224. Chapter 186: Intermediate and Malignant Myofibroblastic/Fibroblastic Tumors - p. 825 225. Chapter 187: Liposarcomas - p. 835 226. Chapter 188: Muscle Sarcomas - p. 845 227. Chapter 189: Intermediate and Malignant Vascular Tumors - p. 855 228. Chapter 190: Malignant Peripheral Nerve Sheath Tumor - p. 863 229. Chapter 191: Representative Genetic Findings in Bone and Soft Tissue Tumors - p. 869 230. SARCOMAS OF UNCERTAIN DIFFERENTIATION - p. 875 231. Chapter 192: Rare Sarcomas of Uncertain Differentiation With Specific Molecular Alterations - p. 875 232. CNS - p. 885 233. Chapter 193: High-Grade Astrocytoma - p. 885 234. Chapter 194: Low-Grade Astrocytoma - p. 889 235. Chapter 195: Pilocytic Astrocytoma - p. 893 236. Chapter 196: Oligodendroglioma - p. 897 237. Chapter 197: Ependymoma - p. 901 238. Chapter 198: Medulloblastoma - p. 907 239. Chapter 199: Choroid Plexus Tumors - p. 913 240. Chapter 200: Meningioma - p. 917 241. Chapter 201: Retinoblastoma - p. 921 242. SECTION 9: QUALITY ASSURANCE AND REGULATORY ISSUES - p. 925 243. Chapter 202: Federal Agencies and Regulation of Laboratories - p. 925 244. Chapter 203: FDA Regulations - p. 929 245. Chapter 204: Proficiency Testing and Accreditation - p. 935 246. INDEX - p. 939

Indice
Autores
Muestra

No hay muestra disponible

Ficha Técnica

No hay ficha técnica disponible